QUICK REFERENCE: Steps to reduce emergency department visits and help your patient by combining withdrawal treatment with craving reduction

1. **Treat Acute Withdrawal**
   Use your preferred strategy/hospital standard practice with benzodiazepine and/or phenobarbital to treat acute withdrawal.

2. **At Discharge**
   a. **Prescribe Medication for protracted withdrawal.**
      **Gabapentin 600mg-900 TID, #42**
      - Avoid/use with caution in renal disease.
      - If history of severe withdrawal may need additional treatment including with benzodiazepines)
   
   b. **Prescribe Medication to reduce craving and relapse.**
      **Naltrexone 50mg PO Daily #14;**
      **Contraindications:**
      - Any opioid use--incl. planned surgery/anesthesia, buprenorphine starts, or OUD
      - Acute liver injury with LFTS > 5x normal
      - Decompensated cirrhosis

3. **Contact the SUN (Substance Use Navigator)**
   The SUN will problem solve, motivate and arrange follow up care.

4. **At follow up**
   Offer 30day Naltrexone injection (Vivitrol)
11 million Americans have an alcohol use disorder while 2 million Americans have an opioid use disorder. Screening, brief intervention, and referral to treatment is proven to decrease risky drinking and alcohol use disorder related behaviors in acute care settings. Targeting patients presenting for trauma may be particularly effective.

This guidance is for hospitals participating in the California Bridge Program who would like to incorporate treatment for alcohol use disorder into their emergency departments and inpatient settings. This is part of the Practice Under Development series presenting information about practices we are piloting and continuing to refine. This guidance does not focus on withdrawal treatment, rather the focus here is on the initiation of medications to decrease cravings and acute care utilization.

**Consider screening:**
- Men < 65 yo: *How many times in the past year have you had 5 or more drinks in a day?*
- All women and men > 65: *How many times in the past year have you had 4 or more drinks in a day?*

**Alcohol withdrawal management:**
- Treat per the protocols of your facility
- Consider phenobarbital, benzodiazepines
- Consider gabapentin (ex: gabapentin 600 mg PO TID #42), caution in renal disease, if severe withdrawal may need additional treatment

**Offer maintenance treatment:**
- First line is naltrexone, which is FDA approved for AUD treatment:
  - **Naltrexone PO:**
    - E.g.: naltrexone 50 mg PO, 1 tab PO qday, dispense #14, 0 refills
  - **Naltrexone IM:**
    - Consider if patients unable to take daily medication, but have tolerated PO naltrexone
    - Naltrexone 380 mg IM x 1 in buttock monthly
    - Covered by MediCal for outpatient treatment, pharmaceutical company may be able to provide acute care doses
  - **Cautions and contraindications:**
    - Avoid if patient has OUD or opioid dependence or is on buprenorphine (recommend at least 7 days off of opioids if physically dependent)—can consider test dose of naloxone or PO naltrexone to ensure no withdrawal
    - Avoid if planned surgery or anesthesia needed
    - Avoid if AST and ALT >5x upper limit of normal or Childs Pugh class C
  - **Adverse effects:**
    - Headache, GI distress, opioid withdrawal, injection site reaction, transaminitis
- Second line: Multiple agents, select based on comorbidities and patient preference (see table below)

**Discharge from acute care with direct linkage to ongoing treatment if possible:** clinic, intensive outpatient program, medically assisted withdrawal (detox) facility, residential treatment as fits patients interest and program availability

More resources available [www.BridgeToTreatment.org](http://www.BridgeToTreatment.org)
**Consider the first dose of IM naltrexone** in acute care for those who have not been able to successfully connect on prior presentations if possible

**Always contact your SUN** who can work with the patient to motivate, make shared decisions, and ensure follow up.

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Target population</th>
<th>Efficacy</th>
<th>Contraindications/ADEs</th>
<th>Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Naltrexone (first line)</strong></td>
<td>First line for most people without contraindications</td>
<td>NNT 9 for return to heavy drinking</td>
<td>Opioid use (risk of withdrawal), planned surgery/anesthesia AST and ALT &gt;5x ULN ADEs: HA, GI distress, opioid w/d, injection site rxn, transaminitis</td>
<td>50 mg PO <strong>qday</strong> OR 380 mg <strong>qmonth</strong></td>
</tr>
<tr>
<td><strong>Topiramate</strong></td>
<td>Consider if also using cocaine, PTSD, seizure hx, overweight</td>
<td>NNT 7.5 for return to heavy drinking 7.5</td>
<td>Dose reduce in CKD Cognitive slowing, weight loss, paresthesias, altered taste, metabolic acidosis Avoid if hx kidney stones, narrow-angle glaucoma</td>
<td>Goal 150 mg <strong>BID</strong> (slowly uptitrate)</td>
</tr>
<tr>
<td><strong>Baclofen</strong></td>
<td>Consider if also chronic pain, liver disease</td>
<td>Not effective in meta-analyses</td>
<td>Dose reduce in CKD Somnolence, dizziness</td>
<td>10-20 mg <strong>TID</strong></td>
</tr>
<tr>
<td><strong>Gabapentin</strong></td>
<td>Consider if neuropathic pain, anxious, EtOH withdrawal Helps when added to naltrexone if naltrexone had some efficacy</td>
<td>Mixed evidence</td>
<td>Dose reduce in CKD Somnolence, dizziness, GI effects, HA Note, some abuse liability and can potentiate opioids</td>
<td>600 mg <strong>TID</strong></td>
</tr>
<tr>
<td><strong>Acamprosate (FDA approved)</strong></td>
<td>Patients who are already abstaining, prevents relapse, safe in liver disease</td>
<td>NNT 9 to reduce risk of any drinking</td>
<td>Dose reduce in CKD Causes diarrhea, fatigue, GI upset</td>
<td>2x 333 mg tablets <strong>TID</strong></td>
</tr>
<tr>
<td><strong>Disulfiram (FDA approved)</strong></td>
<td>Patients who are already abstaining, prevents relapse, only effective if observed dosing by family, opioid treatment program</td>
<td>If not directly observed, outcomes similar to placebo</td>
<td>Causes physical illness if return to use, do not start if ongoing EtOH use Causes metallic taste, hepatotoxicity, optic neuritis, peripheral neuropathy</td>
<td>250-500 mg <strong>qday</strong></td>
</tr>
<tr>
<td><strong>Varenicline</strong></td>
<td>Men who are also smokers</td>
<td>Decreased heavy drinking in male smokers</td>
<td>Dose reduce in CKD Caution in depression</td>
<td>2mg <strong>qday</strong></td>
</tr>
</tbody>
</table>
REFERENCES


California Bridge disseminates resources developed by an interdisciplinary team based on published evidence and medical expertise. These resources are not a substitute for clinical judgment or medical advice. Adherence to the guidance in these resources will not ensure successful patient treatments. Current best practices may change. Providers are responsible for assessing the care and needs of individual patients.

Documents are periodically updated to reflect the most recent evidence-based research. Materials provided through the California Bridge may be utilized for the sole purpose of providing information for the treatment of substance use disorders. Such materials may be distributed with proper attribution from the California Department of Health Care Services, Public Health Institute, California Bridge Program. Questions may be submitted via email to info@BridgeToTreatment.org.

Practice Under Development: Acute Care Treatment of Alcohol Use Disorder, November 2019

More resources available www.BridgeToTreatment.org